<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936909</url>
  </required_header>
  <id_info>
    <org_study_id>RED-HART (HM15339)</org_study_id>
    <secondary_id>1R34HL117026</secondary_id>
    <nct_id>NCT01936909</nct_id>
  </id_info>
  <brief_title>Interleukin-1 Blockade in Recently Decompensated Heart Failure</brief_title>
  <acronym>RED-HART</acronym>
  <official_title>Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The RED-HART is a randomized double-blinded placebo-controlled study of Anakinra (IL-1
      blocker) in patients with recently decompensated heart failure to determine the safety and
      efficacy in terms of aerobic exercise capacity and ventilatory efficiency measured with a
      cardiopulmonary exercise test.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 23, 2016</completion_date>
  <primary_completion_date type="Actual">September 23, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interval Changes in Peak Oxygen Consumption (VO2)</measure>
    <time_frame>Baseline to 2 weeks</time_frame>
    <description>Interval changes in peak oxygen consumption (VO2) after 2 weeks of anakinra treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>12 weeks</time_frame>
    <description>The Duke Activity Status Index questionnaire will be completed at enrollment and 12 weeks. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores represent increased ability to perform daily activities and may be interpreted as improved quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or Hospital Admission for Heart Failure</measure>
    <time_frame>24 weeks</time_frame>
    <description>We will monitor survival and hospitalization for heart failure throughout the 24 week follow-up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Anakinra (short)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anakinra (long)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injections daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (weeks 1-2)</intervention_name>
    <description>Anakinra 100 mg daily for weeks 1 and 2</description>
    <arm_group_label>Anakinra (short)</arm_group_label>
    <arm_group_label>Anakinra (long)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (weeks 3-12)</intervention_name>
    <arm_group_label>Anakinra (long)</arm_group_label>
    <other_name>Anakinra 100 mg daily for weeks 3 through 12</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo daily for week 1 through 12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All 6 criteria need to be met for enrollment of the patient in the study

          1. Primary diagnosis for hospitalization is decompensated heart failure established as
             the finding at admission of all 2 conditions listed below:

               1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion;

               2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least
                  one of the conditions must be met);

                    -  pulmonary congestion/edema at physical exam OR chest X-Ray;

                    -  plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/ml;

                    -  invasive measurement of left ventricular end-diastolic pressure &gt;18 mmHg or
                       of pulmonary artery occluding pressure (wedge) &gt;16 mmHg.

          2. The patient has a prior documentation of impaired left ventricular systolic function
             (ejection fraction &lt;50%) at most recent assessment by any imaging modality (within 12
             months).

          3. The patient is now clinically stable and meets standard criteria for hospital
             discharge as documented by all the 3 conditions listed below:

               1. absence of dyspnea or pulmonary congestion/distress at rest;

               2. absence of pitting edema in the lower extremities, or in any other region;

               3. stable hemodynamic parameters (blood pressure, heart rate).

          4. The patient is of age ≥21 years old, and is willing and able to provide written
             informed consent.

          5. The patient is willing and able to comply with the protocol (i.e. self administration
             of the treatment, and exercise protocol).

          6. The patient has screening plasma C-reactive protein levels &gt;2 mg/L.

        Exclusion Criteria Subjects will not be eligible if they meet any of the following 15
        exclusion criteria.

          1. The primary diagnosis for admission is NOT decompensated heart failure, including
             diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or
             brady-arrhythmias.

          2. Concomitant clinically significant comorbidities that would interfere with the
             execution or interpretation of the study including but not limited to acute coronary
             syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or
             brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders
             affecting respiration.

          3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT),
             coronary artery revascularization procedures, or heart valve surgeries.

          4. Previous or planned implantation of left ventricular assist devices or
             heart-transplant.

          5. Chronic use of intravenous inotropes.

          6. Recent (&lt;14 days) use of immunosuppressive or anti-inflammatory drugs (not including
             Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).

          7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus).

          8. Active infection (of any type);

          9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C
             virus [HCV], and HIV/AIDS).

         10. Prior (within the past 10 years) or current malignancy.

         11. Any comorbidity limiting survival or ability to complete the study.

         12. End stage kidney disease requiring renal replacement therapy.

         13. Neutropenia (&lt;2,000/mm3) or Thrombocytopenia (&lt;50,000/mm3).

         14. Pregnancy.

         15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion
             during cardiopulmonary exercise testing obtained during the baseline testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>November 30, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 22, 2017</results_first_posted>
  <last_update_submitted>November 30, 2017</last_update_submitted>
  <last_update_submitted_qc>November 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
        </group>
        <group group_id="P2">
          <title>Anakinra (Long)</title>
          <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo injections daily for 12 weeks
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
        </group>
        <group group_id="B2">
          <title>Anakinra (Long)</title>
          <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo injections daily for 12 weeks
Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="49.75" upper_limit="60.5"/>
                    <measurement group_id="B2" value="53.5" lower_limit="47.25" upper_limit="60.75"/>
                    <measurement group_id="B3" value="59.5" lower_limit="56.25" upper_limit="66.5"/>
                    <measurement group_id="B4" value="56.5" lower_limit="50.25" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interval Changes in Peak Oxygen Consumption (VO2)</title>
        <description>Interval changes in peak oxygen consumption (VO2) after 2 weeks of anakinra treatment.</description>
        <time_frame>Baseline to 2 weeks</time_frame>
        <population>Patients who completed baseline and 2 week exercise evaluation</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (Long)</title>
            <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo injections daily for 12 weeks
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Interval Changes in Peak Oxygen Consumption (VO2)</title>
          <description>Interval changes in peak oxygen consumption (VO2) after 2 weeks of anakinra treatment.</description>
          <population>Patients who completed baseline and 2 week exercise evaluation</population>
          <units>mL/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.05" lower_limit="11.225" upper_limit="16.15"/>
                    <measurement group_id="O2" value="14.45" lower_limit="11.075" upper_limit="16.575"/>
                    <measurement group_id="O3" value="13.3" lower_limit="11.975" upper_limit="15.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.85" lower_limit="12.525" upper_limit="16.375"/>
                    <measurement group_id="O2" value="14.45" lower_limit="11.075" upper_limit="17.725"/>
                    <measurement group_id="O3" value="12.65" lower_limit="11.575" upper_limit="17.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This test reflects a comparison between baseline and 2 weeks (both rows).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.20</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Improvement</title>
        <description>The Duke Activity Status Index questionnaire will be completed at enrollment and 12 weeks. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores represent increased ability to perform daily activities and may be interpreted as improved quality of life.</description>
        <time_frame>12 weeks</time_frame>
        <population>Patients with baseline and follow-up data</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (Long)</title>
            <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo injections daily for 12 weeks
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Improvement</title>
          <description>The Duke Activity Status Index questionnaire will be completed at enrollment and 12 weeks. The scale ranges from 0 (unable to perform any tasks) to 58.20 (able to perform all tasks). Higher scores represent increased ability to perform daily activities and may be interpreted as improved quality of life.</description>
          <population>Patients with baseline and follow-up data</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.95" lower_limit="17.325" upper_limit="47.2"/>
                    <measurement group_id="O2" value="23.45" lower_limit="15.075" upper_limit="38.6125"/>
                    <measurement group_id="O3" value="22.825" lower_limit="12.7625" upper_limit="40.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.575" lower_limit="23.6375" upper_limit="50.2"/>
                    <measurement group_id="O2" value="34.45" lower_limit="18.2" upper_limit="54.2625"/>
                    <measurement group_id="O3" value="28.7" lower_limit="18.2625" upper_limit="37.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Paired analysis versus baseline</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death or Hospital Admission for Heart Failure</title>
        <description>We will monitor survival and hospitalization for heart failure throughout the 24 week follow-up</description>
        <time_frame>24 weeks</time_frame>
        <population>All analyses were restricted to patients with a minimum of 2 weeks follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
          </group>
          <group group_id="O2">
            <title>Anakinra (Long)</title>
            <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo injections daily for 12 weeks
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Hospital Admission for Heart Failure</title>
          <description>We will monitor survival and hospitalization for heart failure throughout the 24 week follow-up</description>
          <population>All analyses were restricted to patients with a minimum of 2 weeks follow-up.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Log-rank test</non_inferiority_desc>
            <p_value>0.12</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All analyses were restricted to patients with a minimum of 2 weeks follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg daily for 2 weeks, followed by placebo for 10 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2</description>
        </group>
        <group group_id="E2">
          <title>Anakinra (Long)</title>
          <description>Anakinra 100 mg daily for 12 weeks
Anakinra (weeks 1-2): Anakinra 100 mg daily for weeks 1 and 2
Anakinra (weeks 3-12)</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo injections daily for 12 weeks
Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cardiac arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Serious infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Van Tassell</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>8048284583</phone>
      <email>bvantassell@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

